|
|
|
|
|
02.04.26 - 12:48
|
AstraZeneca Overweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - JPMorgan hat Astrazeneca auf "Overweight" mit einem Kursziel von 16000 Pence belassen. Die Aktie steht zudem auf der "Analyst Focus List" der US-Bank. Klinische Phase-III-Studiendaten für eine Kombinationstherapie mit Imfinzi ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.04.26 - 11:00
|
BAT France Confirms the Discontinuation of Sales of Its Nicotine Pouch Products in France (Cision)
|
|
|
Paris, April 2[nd] , 2026 – In accordance with the decree[1] of September 5[th] 2025, which entered into force on April 1[st] , BAT France has ended the sale of its nicotine pouch products in France. This decree now prohibits the production, manufacturing, transport, import, export, possession, offering, transfer, acquisition, and use of oral nicotine products, including portioned pouches.
BAT France acknowledges this decision and fully complies with it.
[1] https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000052197959
However, the company regrets that such a ban was adopted through...
|
|
|
|